Journal of International Oncology ›› 2016, Vol. 43 ›› Issue (8): 711-714.doi: 10.3760/cma.j.issn.1673422X.2016.09.018

Previous Articles     Next Articles

Research progress of thalidomide in usual nonhematologic malignancies

Lei Lei, Wang Xian, Wang Xiaojia   

  1. Department of Breast Tumor Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China
  • Online:2016-09-08 Published:2016-08-04
  • Contact: Wang Xiaojia E-mail:wxiaojia0803@163.com
  • Supported by:

    National Natural Science Foundation of China (81572715); Medical and Health Science and Technology Project of Zhejiang Province (2015KYB052, 2013KYB034); Traditional Chinese Medicine Program of Zhejiang Province (2013ZA020)

Abstract: Thalidomide has antitumor effects such as antitumor angiogenesis, improvement of immune function and cachexia of patients with advanced tumors, which has been effectively used in elderly patients with castrationresistant prostate cancer, chemotherapy resistant advanced colorectal cancer, advanced hepatocellular carcinoma and metastatic breast cancer. As the indepth study of the antitumor mechanism of thalidomide, more and more clinical researches have focused on the function of thalidomide on nonhematological malignancies, especially it has obtained some achivements in the postoperative adjuvant therapy for highrisk colorectal cancer and primary hepatocellular carcinoma and the salvage therapy for metastatic triplenegative breast cancer and refractory gynecological tumor.

Key words: Neoplasms, Therapeutic uses, Thalidomide